These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9541615)

  • 1. Identification of a conserved neutralization site in the first heptad repeat of the fusion protein of respiratory syncytial virus.
    Langedijk JP; Meloen RH; van Oirschot JT
    Arch Virol; 1998; 143(2):313-20. PubMed ID: 9541615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein.
    López JA; Andreu D; Carreño C; Whyte P; Taylor G; Melero JA
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2567-77. PubMed ID: 7506298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus.
    Arbiza J; Taylor G; López JA; Furze J; Wyld S; Whyte P; Stott EJ; Wertz G; Sullender W; Trudel M
    J Gen Virol; 1992 Sep; 73 ( Pt 9)():2225-34. PubMed ID: 1383404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding of neutralizing monoclonal antibodies to regions of the fusion protein of respiratory syncytial virus expressed in Escherichia coli.
    Lounsbach GR; Bourgeois C; West WH; Robinson JW; Carter MJ; Toms GL
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2559-65. PubMed ID: 7506297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
    Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
    J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory syncytial virus fusion glycoprotein: further characterization of a major epitope involved in virus neutralization.
    Trudel M; Nadon F; Séguin C; Payment P; Talbot PJ
    Can J Microbiol; 1987 Oct; 33(10):933-8. PubMed ID: 2446731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
    Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
    Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective epitopes on the fusion protein of respiratory syncytial virus recognized by murine and bovine monoclonal antibodies.
    Taylor G; Stott EJ; Furze J; Ford J; Sopp P
    J Gen Virol; 1992 Sep; 73 ( Pt 9)():2217-23. PubMed ID: 1383403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenic analysis of the F protein of the bovine respiratory syncytial virus: identification of two distinct antigenic sites involved in fusion inhibition.
    Matheise JP; Walravens K; Collard A; Coppe P; Letesson JJ
    Arch Virol; 1995; 140(6):993-1005. PubMed ID: 7541983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of synthetic peptides to locate neutralizing antigenic domains on the fusion protein of respiratory syncytial virus.
    Bourgeois C; Corvaisier C; Bour JB; Kohli E; Pothier P
    J Gen Virol; 1991 May; 72 ( Pt 5)():1051-8. PubMed ID: 2033389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the bovine respiratory syncytial virus fusion protein (F) using monoclonal antibodies.
    Pastey MK; Samal SK
    Vet Microbiol; 1997 Nov; 58(2-4):175-85. PubMed ID: 9453129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein.
    Mousa JJ; Kose N; Matta P; Gilchuk P; Crowe JE
    Nat Microbiol; 2017 Jan; 2():16271. PubMed ID: 28134924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function.
    Beeler JA; van Wyke Coelingh K
    J Virol; 1989 Jul; 63(7):2941-50. PubMed ID: 2470922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies.
    Anderson LJ; Bingham P; Hierholzer JC
    J Virol; 1988 Nov; 62(11):4232-8. PubMed ID: 2459412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein.
    Crowe JE; Firestone CY; Crim R; Beeler JA; Coelingh KL; Barbas CF; Burton DR; Chanock RM; Murphy BR
    Virology; 1998 Dec; 252(2):373-5. PubMed ID: 9878616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide mimics of a conformationally constrained protective epitopes of respiratory syncytial virus fusion protein.
    Chargelegue D; Obeid OE; Shaw DM; Denbury AN; Hobby P; Hsu SC; Steward MW
    Immunol Lett; 1997 Jun; 57(1-3):15-7. PubMed ID: 9232419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins.
    García-Barreno B; Palomo C; Peñas C; Delgado T; Perez-Breña P; Melero JA
    J Virol; 1989 Feb; 63(2):925-32. PubMed ID: 2463385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and characterization of monoclonal antibodies directed against five structural components of human respiratory syncytial virus subgroup B.
    Orvell C; Norrby E; Mufson MA
    J Gen Virol; 1987 Dec; 68 ( Pt 12)():3125-35. PubMed ID: 2447224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibody based in vitro potency assay as a predictor of antigenic integrity and in vivo immunogenicity of a Respiratory Syncytial Virus post-fusion F-protein based vaccine.
    Djagbare MD; Yu L; Parupudi A; Sun J; Coughlin ML; Rush BS; Sanyal G
    Vaccine; 2018 Mar; 36(12):1673-1680. PubMed ID: 29456016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis of respiratory syncytial virus neutralization by motavizumab.
    McLellan JS; Chen M; Kim A; Yang Y; Graham BS; Kwong PD
    Nat Struct Mol Biol; 2010 Feb; 17(2):248-50. PubMed ID: 20098425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.